The Meals and Drug Administration is refusing to contemplate Moderna’s utility for a brand new flu vaccine made with Nobel Prize-winning mRNA expertise, the corporate introduced Tuesday.
The information is the newest signal of the FDA’s heightened scrutiny of vaccines underneath Well being and Human Companies Secretary Robert F. Kennedy Jr., notably these utilizing mRNA expertise, which he has criticized earlier than and after changing into the nation’s high well being official.
Moderna says it acquired what known as a “refusal-to-file” letter from the FDA that objected to the way it carried out a 40,000-person medical trial evaluating its new vaccine to one of many customary flu pictures used as we speak. That trial concluded the brand new vaccine was considerably more practical in adults 50 and older than that customary shot.
The letter from FDA vaccine director Dr. Vinay Prasad stated the company does not take into account the appliance to include an “satisfactory and well-controlled trial” as a result of it did not evaluate the brand new shot to “the best-available customary of care in the US on the time of the research.” Prasad’s letter — which Moderna revealed on-line — pointed to some recommendation that FDA officers gave Moderna in 2024, underneath the Biden administration, which Moderna did not observe.
Based on Moderna, that suggestions stated it was acceptable to make use of the standard-dose flu shot the corporate had chosen — however that one other model particularly beneficial for seniors can be most popular for anybody 65 and older within the research. Nonetheless, Moderna stated, the FDA did comply with let the research proceed as initially deliberate.
The corporate stated it additionally had shared with the FDA further knowledge from a separate trial evaluating the brand new vaccine in opposition to a licensed high-dose shot used for seniors.
The FDA “didn’t determine any security or efficacy considerations with our product” and “doesn’t additional our shared objective of enhancing America’s management in growing modern medicines,” Moderna CEO Stephane Bancel stated in a press release.
Andrew Nixon, a spokesperson for the Division of Well being and Human Companies, stated in a press release that the FDA “rejected Moderna’s utility for submitting as a result of the corporate refused to observe very clear FDA steerage from 2024 to check its product in a medical trial in opposition to a CDC-recommended flu vaccine to check security and efficacy.”
“Essentially the most protecting flu pictures for seniors are a subset of excessive dose flu pictures beneficial by the CDC Advisory Committee on Immunization Practices, which might have served as the right management on this research,” Nixon stated.
It is uncommon for FDA to refuse to file an utility, notably for a brand new vaccine, which requires firms and FDA employees to interact in months or years of discussions.
Moderna has requested an pressing assembly with the FDA, and famous that it has utilized for the vaccine’s approval in Europe, Canada and Australia.
Within the final yr, FDA officers working underneath Kennedy have rolled again suggestions round COVID-19 pictures, added further warnings to the 2 main COVID vaccines — that are made with mRNA expertise — and eliminated critics of the administration’s method from an FDA advisory panel.
Kennedy introduced final yr that his division would cancel greater than $500 million in contracts and funding for the event of vaccines utilizing mRNA, zeroing in on analysis into coronavirus and flu vaccines.
Kennedy stated the Division of Well being and Human Companies had decided that “mRNA expertise poses extra threat than advantages for these respiratory viruses.” Vaccine specialists condemned the choice, with Jerome Adams, who served as surgeon normal in President Trump’s first time period, writing on social media, “fairly frankly this transfer goes to price lives.”
The FDA for many years has allowed vaccine makers to shortly replace their annual flu pictures to focus on the newest strains by displaying that they set off an immune response in sufferers. That is a much more environment friendly method than working long-term research monitoring whether or not sufferers get the flu and the way they fare.
In an inside memo final yr, Prasad wrote that the streamlined technique would now not be permitted – main greater than a dozen former FDA commissioners to pen an editorial condemning the statements.
Democratic Sen. Patty Murray of Washington condemned the FDA’s choice on Moderna, saying Kennedy’s staff was “blocking an up to date flu vaccine for no purpose grounded in science.”
“American vaccine coverage has been hijacked by a conspiracy theorist—but most Republicans are blissful to only sit on their arms,” Murray wrote on X.
